Last Update Time:
28-Feb-2025 16:00:00
ISIN:
INE385I01010
Sector:
Healthcare
Symbol:
ALPA
Alpa Laboratories Limited
₹97.21
₹-8.32
(-7.88%)
▼
Prev. Close
₹105.53
Open
₹103.95
Close
₹97.60
Range
₹92.35 - ₹102.07
High
₹103.95
Low
₹97.00
Ind. Close
₹0.00
VWAP
₹98.61
The current stock price of Alpa Laboratories Limited is ₹97.21, with a target price range between ₹92.35 and ₹102.07. The stock has experienced a price change of ₹-8.32 (-7.88%), reflecting recent market volatility.
Today's opening price was ₹103.95, while the previous close stood at ₹105.53.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Alpa Laboratories Limited Price Chart
Alpa Laboratories Limited Pre Open Market Overview: 28-Feb-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 103.95
- Previous Close Price: 105.53
- Change: -1.58%
- Total Traded Volume: 223
- Total Buy Quantity: 383
- Total Sell Quantity: 8,881
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 101.00 | 5.00 | 0.00 |
| 101.35 | 39.00 | 0.00 |
| 102.53 | 1.00 | 0.00 |
| 103.50 | 15.00 | 0.00 |
| 103.95 | 55.00 | 0.00 |
| 107.00 | 0.00 | 5,066.00 |
| 107.30 | 0.00 | 25.00 |
| 107.60 | 0.00 | 50.00 |
| 108.00 | 0.00 | 600.00 |
| 108.50 | 0.00 | 347.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 383
Total Sell Quantity: 8881
Shareholding Patterns of Alpa Laboratories Limited
Key Trade Statistics of Alpa Laboratories Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.83 |
| Traded Value (₹ Cr.) | 0.82 |
| Total Market Cap (₹ Cr.) | 204.54 |
| Free Float Market Cap (₹ Cr.) | 87.35 |
| Impact cost | 0.56 |
| Quantity Traded | 83,022.00 |
| Deliverable Quantity | 56,897.00 |
| % of Quantity to Traded | 68.53 |
| Security VaR | 20.35 |
| Index VaR | N/A |
| VaR Margin | 20.35 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 23.85 |
| Face Value | 10 |
Key Price Statistics of Alpa Laboratories Limited
The 52-week high for Alpa Laboratories Limited was ₹144.50, recorded on 30-Sep-2024. On the other hand, the 52-week low stands at ₹69.90, with the lowest value recorded on 04-Jun-2024.
The upper band for trading is ₹126.63, and the lower band is ₹84.42. The price band is 20%.
The stock's daily volatility stands at 3.09, while the annualized volatility is 59.03. The tick size for trading is ₹0.01.
| Price Information | Details |
|---|---|
| 52 Week High (30-Sep-2024) | 144.50 |
| 52 Week Low (04-Jun-2024) | 69.90 |
| Upper Band | 126.63 |
| Lower Band | 84.42 |
| Price Band (%) | 20 |
| Daily Volatility | 3.09 |
| Annualised Volatility | 59.03 |
| Tick Size | 0.01 |
Key Securities Statistics of Alpa Laboratories Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 06-Aug-2007 |
| Adjusted P/E | 8.14 |
| Symbol P/E | 8.14 |
| Index | NA |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Alpa Laboratories Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Alpa Laboratories Limited
| Subject | Date |
|---|---|
| Integrated Filing- Financial | 17-Feb-2025 |
| General Updates | 14-Feb-2025 |
| Financial Result Updates | 14-Feb-2025 |
| Updates | 13-Feb-2025 |
| Outcome of Board Meeting | 13-Feb-2025 |
| Disclosure of material issue | 07-Feb-2025 |
| Board Meeting Intimation | 03-Feb-2025 |
| Trading Window | 30-Dec-2024 |
Corporate Actions of Alpa Laboratories Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | Annual General Meeting | 20-Sep-2024 |
| 10 | Annual General Meeting | 21-Sep-2023 |
| 10 | Annual General Meeting | 20-Sep-2022 |
| 10 | Annual General Meeting | 20-Sep-2021 |
| 10 | Annual General Meeting | 18-Sep-2020 |
| 10 | Annual General Meeting | 19-Sep-2019 |
| 10 | Annual General Meeting | 19-Sep-2018 |
| 10 | Annual General Meeting | 20-Sep-2017 |
| 10 | Annual General Meeting | 21-Sep-2016 |
| 10 | Annual General Meeting | 16-Sep-2015 |
| 10 | Annual General Meeting | 24-Sep-2014 |
| 10 | Annual General Meeting | 31-Jul-2013 |
| 10 | Annual General Meeting | 21-Sep-2012 |
| 10 | Annual General Meeting | 22-Sep-2011 |
| 10 | Annual General Meeting | 02-Sep-2010 |
| 10 | Annual General Meeting | 23-Jul-2009 |
| 10 | Annual General Meeting | 18-Sep-2008 |
Board Meetings of Alpa Laboratories Limited
Financial Results of Alpa Laboratories Limited
Company Directory of Alpa Laboratories Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.alpalabs.in | Registered Office | 33/2, Pigdamber, A.B. Road, Rau, | INDORE |
| www.alpalabs.in | Transfer Agent | Bigshare Services Private Limited 1st Floor Bharat Tin Works Building Opp. Vasant Oasis, Makwana Road Marol, Andheri East | MUMBAI |
Insider Trading of Alpa Laboratories Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | SHITUL SHAH | 0 | Buy |
| 7(2) | Asha Chawla | 0 | Buy |
| 7(2) | M.S. CHAWLA | 0 | Buy |
| 7(2) | M.S. CHAWLA | 20175000 | Sell |
| 7(2) | RIMA SHAH | 5245500 | Buy |
| 7(2) | PRAVIN SHAH | 4438500 | Buy |
| 7(2) | SHITUL SHAH | 10491000 | Buy |
| 7(2) | M.S. CHAWLA | 61454879 | Buy |
| 7(2) | PARESH CHAWLA | 88229757 | Buy |
| 7(2) | P.R. Patel | 20309669 | Sell |
| 7(2) | Neil J. Patel u/g Jayesh Patel | 10819692 | Sell |
| 7(2) | Nayana J. Patel | 20518071 | Sell |
| 7(2) | Jayesh P. Patel (HUF) | 16372675 | Sell |
| 7(2) | Jayesh Patel | 51633600 | Sell |
| 7(2) | Kamlaben P. Patel | 16827460 | Sell |
| 7(2) | P.R. Patel (HUF) | 13195520 | Sell |
| 7(2) | Jayesh Patel | 29787175 | Buy |
| 7(2) | Amita Patel | 8303625 | Sell |
| 7(2) | Chhaya Chandel | 12305700 | Sell |
| 7(2) | Jayana Patel | 7668375 | Sell |
Annual Reports of Alpa Laboratories Limited
Investor Complaints of Alpa Laboratories Limited
Event Calendar of Alpa Laboratories Limited
| Purpose | Details |
|---|---|
| Results/Others | To consider and approve the financial results for the quarter and period ended June 30, 2010 along with other routine business. |
| Financial Results | To consider and approve the financial results for the quarter and period ended September 30, 2010 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended December 31, 2010 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended March 31, 2011 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended June 30, 2011 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended September 30, 2011 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter ended December 31, 2011 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended March 31, 2012 along with other routine business. |
| Financial Results | To consider and approve the financial results for the quarter and period ended on June 30, 2012 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended September 30, 2012 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended December 31, 2012 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended March 31, 2013 along with other routine business. |
| Results | To consider and approve the financial results for the quarter ended June 30, 2013 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended September 30, 2013 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended December 31, 2013 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended March 31, 2014 along with other routine business. Further, in terms of the Code for Corporate Disclosure Practices and Code of Conduct for Prevention of Insider Trading pursuant to the provisions of Securities and Exchange Board of India ( Prohibition of Insider Trading) Regulation s, 1992 adopted by the Company, the Company has informed all the "concerned persons" that the Trading Window of the Company will be closed for Directors/ Employees from May 20, 2014 to May 31, 2014 (both days inclusive) in connection with the Company" s Board Meeting as scheduled above. |
| Results | To consider and approve the financial results for the quarter and period ended June 30, 2014 along with other routine business. Further, in terms of the Code for Corporate Disclosure Practices and Code of Conduct for prevention of Insider Trading pursuant to the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 adopted by the Company, the Company has informed all the "concerned persons" that the Trading Window of the Company will be closed for Directors/ Empolyees from July 31, 2014 to Aug 09, 2014 (both days inclusive) in connection with the Company's Board Meeting as schedule above. |
| Results/Others | To consider and approve the financial results for the quarter and period ended September 30, 2014 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended December 31, 2014 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended March 31, 2015 along with other routine business. |
| Results/Others | to consider and approve the financial results for the quarter and period ended June 30, 2015 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended September 30, 2015 along with other routine business. |
| Results/Others | To consider and approve the financial results for the quarter and period ended 31st December 2015 along with other routine business. |
| Results/Others | Inter alia:1. To consider the standalone and consolidated audited financial results of the Company for quarter and period ended 31 t March, 2016.2. To Take on record of appointment of Company Secretary Cum Compliance Officer3. To Appoint Managing Director of the company. |
| Results/Others | Inter alia, to consider the following business :1. To consider and approve the unaudited standalone financial results of the Company and Limited Review Report for quarter ended June 30, 2016.2. And any other business which board may consider.In connection with the above, as per the Company`s Code of Conduct to regulate, monitor and report trading by insiders, adopted by the Board pursuant to SEBI (Prohibition of Insider Trading) Regulation, 2015, the trading window for dealing in the securities of the Company is closed for the Directors/Designated Employees from August 2, 2016 to August 14, 2016 (both days inclusive) |
| Results/Others | , interalia to consider the following business: (1) To consider and approve the un audited financial results standalone Financial Results and limited review report for quarter and period September 30, 2016.(2) And any other business which board may consider. |
| Results/Others | interalia to consider the following business: (1) To consider and approve the un audited standalone Financial Results and limited review report for quarter ended December 31, 2016.(2) And any other business which board may consider. |
| Results | Inter alia, to consider: 1. To consider the standalone and consolidated audited financial results of the Company for quarter and period ended March 31, 2017. |
| Results/Others | Inter alia, to consider the following business : 1. To consider and approve the unaudited standalone financial results of the Company and Limited Review Report for quarter ended June 30, 2017. 2. To approve the notice of Annual General Meeting of the members of the Company. 3. To consider the matter of merger of the wholly owned subsidiary company with The Company subject to approval of members in General Meeting. 4.And any other business which board may consider. |
| Results/Others | To consider the items as specified in the agenda. |
| Results/Others | inter-alia, to consider: 1.the Unaudited standalone Financial Results for the quarter ended September 30,2017 along with limited review report. (2) And any other business which board may consider. |
| Results/Others | inter alia to consider the following business: (1) To consider and approve the un audited standalone Financial Results and limited review report from the Statutory Auditor for quarter ended December 31, 2017.(2) And any other business which board may consider. |
| Financial Results | To consider inter alia, the following Businesses: 1) The Audited Financial Results of the Company for the quarter and year ended March 31, 2018. 2) The Audited Financial Results of the Company and its subsidiaries for the quarter and year ended March 31, 2018. |
| Financial Results/Other business matters | Inter alia, to consider the following business: 1) To consider and approve the Un-audited Standalone Financial Results result of the Company along with Limited Review Report for quarter ended June 30, 2018. 2) To approve the Notice of Annual General Meeting of the Company. |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019. |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2021 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Alpa Laboratories Limited has informed the Exchange about Board Meeting to be held on 14-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2023 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2024 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2024 and other business matters |
Share Transfers of Alpa Laboratories Limited
Voting Results of Alpa Laboratories Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 28-SEP-2024 | AGM | Adoption of Audited Standalone Financial Statements, Directors Report and Auditors Report for the Year ended 31st March 2024. |
| 28-SEP-2024 | AGM | Appointment of Mr. Pravin Shah as the whole time director of the company who has attained age above 70 years. |
| 28-SEP-2024 | AGM | Appointment of Mr. Mahendra Singh Chawla as the whole time director of the company who has attained age above 70 years. |
| 28-SEP-2024 | AGM | To Approve Limits to make investment or to give loan/guarantee or provide security under section 186 of the Companies Act, 2013 |
| 28-SEP-2024 | AGM | Appointment of Mr. Pratik Shah as an Independent Director of the Company. |
| 28-SEP-2024 | AGM | Ratification of Remuneration Of Cost Auditors Of The Company For The Year 2024-25. |
| 28-SEP-2024 | AGM | Appointment of director who is liable to retire by rotation. |
| 28-SEP-2024 | AGM | Adoption of Audited Consolidated Financial Statements, Directors Report and Auditors Report for the Year ended 31st March 2024. |
| 29-SEP-2023 | AGM | Adoption of Audited Standalone Financial Statements, Directors Report and Auditors Report for the Year ended 31st March 2023. |
| 29-SEP-2023 | AGM | Re-classification of Promoter |
| 29-SEP-2023 | AGM | Appointment of Mr. Sunil Valecha as an Independent Director of the Company. |
| 29-SEP-2023 | AGM | Appointment of Mrs. Pratibha Lunawat as an Independent Director of the Company. |
| 29-SEP-2023 | AGM | Appointment of Mr. Sanket Baheti as an Independent Director of the Company. |
| 29-SEP-2023 | AGM | Appointment of Mr. Shitul Shah as Whole-Time Director of the Company. |
| 29-SEP-2023 | AGM | Ratification of Remuneration Of Cost Auditors Of The Company For The Year 2023-24. |
| 29-SEP-2023 | AGM | Appointment of director who is liable to retire by rotation. |
| 29-SEP-2023 | AGM | Adoption of Audited Consolidated Financial Statements, Directors Report and Auditors Report for the Year ended 31st March 2023. |
| 29-SEP-2022 | AGM | Adoption of Audited Standalone Financial Statements, Directors Report and Auditors Report for the Year ended 31st March 2022. |
| 29-SEP-2022 | AGM | Appointment of director who is liable to retire by rotation. |
| 29-SEP-2022 | AGM | Adoption of Audited Consolidated Financial Statements, Directors Report and Auditors Report for the Year ended 31st March 2022. |
FAQs on Alpa Laboratories Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.